Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Concerned about drug–drug interactions between DOACs and prostate cancer therapies?
New study of 2297 patients from Ontario and Alberta:
- No elevated risk for thrombosis with DOACs plus enzalutamide/ apalutamide
- No elevated risk for bleeding with DOAC plus abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M. Sood
Read the Full Article on Cancer
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe